Curevac strengthens ongoing patent litigations bringing additional cases under new intellectual property rights

Cases in germany and the u.s. broadened by asserting additional, new intellectual property rights three new intellectual property rights added to infringement lawsuit against pfizer/biontech in germany, increasing number of asserted intellectual property rights to eight tenth patent added to curevac's counterclaim against pfizer/biontech in the u.s., covering innovations in mrna purification methods highly relevant to the manufacturing of comirnaty® tÜbingen, germany / accesswire / july 13, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that it has strengthened its position in the ongoing patent litigations with pfizer/biontech in germany and the u.s. by expanding the scope of both cases by asserting new intellectual property rights.
CVAC Ratings Summary
CVAC Quant Ranking